{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:01:30Z","timestamp":1794744090712,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fonds voor Wetenschappelijk Onderzoek (FWO) fellow","award":["1S08516N"],"award-info":[{"award-number":["1S08516N"]}]},{"DOI":"10.13039\/501100003130","name":"Fonds voor Wetenschappelijk Onderzoek","doi-asserted-by":"crossref","award":["S007918N"],"award-info":[{"award-number":["S007918N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003130","name":"Fonds voor Wetenschappelijk Onderzoek","doi-asserted-by":"crossref","award":["S007918N"],"award-info":[{"award-number":["S007918N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Vlaams Instituut voor Biotechnologie","doi-asserted-by":"publisher","award":["Grand Challenges"],"award-info":[{"award-number":["Grand Challenges"]}],"id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Vlaams Instituut voor Biotechnologie","doi-asserted-by":"publisher","award":["Grand Challenges"],"award-info":[{"award-number":["Grand Challenges"]}],"id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Vlaams Instituut voor Biotechnologie","doi-asserted-by":"publisher","award":["Grand Challenges"],"award-info":[{"award-number":["Grand Challenges"]}],"id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Vlaams Instituut voor Biotechnologie","doi-asserted-by":"publisher","award":["Grand Challenges"],"award-info":[{"award-number":["Grand Challenges"]}],"id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARF-22-928639"],"award-info":[{"award-number":["AARF-22-928639"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017506","name":"Alzheimer\u2019s Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Geneeskundige Stichting Koningin Elisabeth"},{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","award":["Methusalem"],"award-info":[{"award-number":["Methusalem"]}],"id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The blood brain barrier (BBB) limits the therapeutic perspective for central nervous system (CNS) disorders. Previously we found an anti-mouse transferrin receptor (TfR) VHH (Nb62) that was able to deliver a biologically active neuropeptide into the CNS in mice. Here, we aimed to test its potential to shuttle a therapeutic relevant cargo. Since this VHH could not recognize the human TfR and hence its translational potential is limited, we also aimed to find and validate an anti-human transferrin VHH to deliver a therapeutic cargo into the CNS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Alpaca immunizations with human TfR, and subsequent phage selection and screening for human TfR binding VHHs was performed to find a human TfR specific VHH (Nb188). Its ability to cross the BBB was determined by fusing it to neurotensin, a neuropeptide that reduces body temperature when present in the CNS but is not able to cross the BBB on its own. Next, the anti\u2013\u03b2-secretase 1 (BACE1) 1A11 Fab and Nb62 or Nb188 were fused to an Fc domain to generate heterodimeric antibodies (1A11AM-Nb62 and 1A11AM-Nb188). These were then administered intravenously in wild-type mice and in mice in which the murine apical domain of the TfR was replaced by the human apical domain (hAPI KI). Pharmacokinetic and pharmacodynamic (PK\/PD) studies were performed to assess the concentration of the heterodimeric antibodies in the brain over time and the ability to inhibit brain-specific BACE1 by analysing the brain levels of A\u03b2<jats:sub>1\u201340<\/jats:sub>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Selections and screening of a phage library resulted in the discovery of an anti-human TfR VHH (Nb188). Fusion of Nb188 to neurotensin induced hypothermia after intravenous injections in hAPI KI mice. In addition, systemic administration 1A11AM-Nb62 and 1A11AM-Nb188 fusions were able to reduce A\u03b2<jats:sub>1-40<\/jats:sub> levels in the brain whereas 1A11AM fused to an irrelevant VHH did not. A PK\/PD experiment showed that this effect could last for 3\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We have discovered an anti-human TfR specific VHH that is able to reach the CNS when administered systemically. In addition, both the currently discovered anti-human TfR VHH and the previously identified mouse-specific anti-TfR VHH, are both able to shuttle a therapeutically relevant cargo into the CNS. We suggest the mouse-specific VHH as a valuable research tool in mice and the human-specific VHH as a moiety to enhance the delivery efficiency of therapeutics into the CNS in human patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12987-022-00374-4","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T13:02:54Z","timestamp":1664802174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["VHHs as tools for therapeutic protein delivery to the central nervous system"],"prefix":"10.1186","volume":"19","author":[{"given":"Yessica","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Jaspers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ru\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Serneels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"De Strooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Dewilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"374_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrd2094","volume":"6","author":"MN Pangalos","year":"2007","unstructured":"MN Pangalos LE Schechter O Hurko 2007 Drug development for CNS disorders: strategies for balancing risk and reducing attrition Nat Rev Drug Discov 6 521 532","journal-title":"Nat Rev Drug Discov"},{"key":"374_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","volume":"120","author":"P-O Freskg\u00e5rd","year":"2017","unstructured":"P-O Freskg\u00e5rd E Urich 2017 Antibody therapies in CNS diseases Neuropharmacol 120 38 55","journal-title":"Neuropharmacol"},{"key":"374_CR3","first-page":"1","volume":"27","author":"T Okuyama","year":"2018","unstructured":"T Okuyama 2018 Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial Mol Ther 27 1 9","journal-title":"Mol Ther"},{"key":"374_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","volume":"13","author":"R Giugliani","year":"2018","unstructured":"R Giugliani 2018 Neurocognitive and somatic stabilization in pediatric patients with severe mucopolysaccharidosis type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1\u20132 trial Orphanet J Rare Dis 13 110","journal-title":"Orphanet J Rare Dis"},{"key":"374_CR5","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1124\/dmd.109.028787","volume":"37","author":"RJ Boado","year":"2009","unstructured":"RJ Boado WM Pardridge 2009 Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey Drug Metab Dispos 37 2299 2304","journal-title":"Drug Metab Dispos"},{"key":"374_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/protein\/12.9.787","volume":"12","author":"JY Li","year":"1999","unstructured":"JY Li 1999 Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein Protein Eng 12 787 796","journal-title":"Protein Eng"},{"key":"374_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"G Hultqvist S Syv\u00e4nen XT Fang L Lannfelt D Sehlin 2017 Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor Theranostics 7 308 318","journal-title":"Theranostics"},{"key":"374_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"J Niewoehner 2014 Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle Neuron 81 49 60","journal-title":"Neuron"},{"key":"374_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/scitranslmed.aay1163","volume":"12","author":"JC Ullman","year":"2020","unstructured":"JC Ullman 2020 Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice Sci Transl Med 12 1163","journal-title":"Sci Transl Med"},{"key":"374_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/scitranslmed.aay1359","volume":"12","author":"MS Kariolis","year":"2020","unstructured":"MS Kariolis 2020 Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys Sci Transl Med 12 1359","journal-title":"Sci Transl Med"},{"key":"374_CR11","doi-asserted-by":"publisher","first-page":"13272","DOI":"10.1096\/fj.202000610RR","volume":"34","author":"D Sehlin","year":"2020","unstructured":"D Sehlin 2020 Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle FASEB J 34 13272 13283","journal-title":"FASEB J"},{"key":"374_CR12","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001787R","volume":"35","author":"P Stocki","year":"2021","unstructured":"P Stocki 2021 Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1 FASEB J 35 e21172","journal-title":"FASEB J"},{"key":"374_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.11.024","author":"YJY Zuchero","year":"2015","unstructured":"YJY Zuchero 2015 Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies Neuron https:\/\/doi.org\/10.1016\/j.neuron.2015.11.024","journal-title":"Neuron"},{"key":"374_CR14","first-page":"22208","volume":"36","author":"W Alata","year":"2022","unstructured":"W Alata 2022 Targeting insulin-like growth factor-1 receptor (IGF1R) for brain delivery of biologics FASEB J Off Publ Fed Am Soc Exp Biol 36 22208","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"374_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12987-020-00226-z","volume":"17","author":"Y Wouters","year":"2020","unstructured":"Y Wouters T Jaspers B Strooper De M Dewilde 2020 Identification and in vivo characterization of a brain-penetrating nanobody Fluids Barriers CNS 17 62","journal-title":"Fluids Barriers CNS"},{"key":"374_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","volume":"9","author":"S Muyldermans","year":"2020","unstructured":"S Muyldermans 2020 Applications of nanobodies Annu Rev Anim Biosci 9 401 21","journal-title":"Annu Rev Anim Biosci"},{"key":"374_CR17","doi-asserted-by":"publisher","first-page":"17408","DOI":"10.1074\/jbc.M112.435289","volume":"288","author":"OV Kovalenko","year":"2013","unstructured":"OV Kovalenko 2013 Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis J Biol Chem 288 17408 17419","journal-title":"J Biol Chem"},{"key":"374_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3389\/fimmu.2017.01361","volume":"8","author":"J Steven","year":"2017","unstructured":"J Steven 2017 In vitro maturation of a humanized shark vnar domain to improve its biophysical properties to facilitate clinical development Front Immunol 8 1361","journal-title":"Front Immunol"},{"key":"374_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"M Scully 2019 Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura N Engl J Med 380 335 346","journal-title":"N Engl J Med"},{"key":"374_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0989-0","author":"S Duggan","year":"2018","unstructured":"S Duggan 2018 Caplacizumab: first global approval Drugs https:\/\/doi.org\/10.1007\/s40265-018-0989-0","journal-title":"Drugs"},{"key":"374_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/d41573-019-00104-w","volume":"18","author":"C Morrison","year":"2019","unstructured":"C Morrison 2019 Nanobody approval gives domain antibodies a boost Nat Rev Drug Discov 18 485 487","journal-title":"Nat Rev Drug Discov"},{"key":"374_CR22","unstructured":"FDA. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma (2022)."},{"key":"374_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","volume":"82","author":"A Markham","year":"2022","unstructured":"A Markham 2022 Envafolimab: first approval Drugs 82 235 240","journal-title":"Drugs"},{"key":"374_CR24","unstructured":"Taisho Pharmaceuticals. Notification of Application for Approval to Manufacture and Market Anti-TNF\u03b1 multivalent NANOBODY\u00ae compound (ozoralizumab) in Japan. Taisho Pharmaceutical Holdings https:\/\/www.taisho.co.jp\/global\/news\/2021\/20210322000753.html."},{"key":"374_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1254\/fpj.21080","volume":"157","author":"R Yamamoto","year":"2022","unstructured":"R Yamamoto S Kawashima 2022 Pharmacological property, mechanism of action and clinical study results of pabinafusp Nihon Yakurigaku Zasshi Folia Pharmacol Jpn 157 62 75","journal-title":"Nihon Yakurigaku Zasshi Folia Pharmacol Jpn"},{"key":"374_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20131660","volume":"211","author":"N Bien-Ly","year":"2014","unstructured":"N Bien-Ly 2014 Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants J Exp Med 211 233 244","journal-title":"J Exp Med"},{"key":"374_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/jnc.14482","volume":"146","author":"AS Haqqani","year":"2018","unstructured":"AS Haqqani 2018 Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity J Neurochem 146 735 752","journal-title":"J Neurochem"},{"issue":"84","key":"374_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/scitranslmed.3002230","volume":"3","author":"YJ Yu","year":"2011","unstructured":"YJ Yu 2011 Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci Transl Med 3 84 44","journal-title":"Sci Transl Med"},{"key":"374_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nprot.2014.039","volume":"9","author":"E Pardon","year":"2014","unstructured":"E Pardon 2014 A general protocol for the generation of Nanobodies for structural biology Nat Protoc 9 674 693","journal-title":"Nat Protoc"},{"key":"374_CR30","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1128\/AAC.45.10.2807-2812.2001","volume":"45","author":"KE Conrath","year":"2001","unstructured":"KE Conrath 2001 Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae Antimicrob Agents Chemother 45 2807 2812","journal-title":"Antimicrob Agents Chemother"},{"key":"374_CR31","doi-asserted-by":"publisher","first-page":"8677","DOI":"10.1074\/jbc.M110.194860","volume":"286","author":"L Zhou","year":"2011","unstructured":"L Zhou 2011 Inhibition of \u03b2-secretase in vivo via antibody binding to unique loops (D and F) of BACE1 J Biol Chem 286 8677 8687","journal-title":"J Biol Chem"},{"key":"374_CR32","doi-asserted-by":"publisher","first-page":"7557","DOI":"10.1038\/s41598-020-64536-w","volume":"10","author":"TC Nesspor","year":"2020","unstructured":"TC Nesspor 2020 High-Throughput generation of bipod (Fab \u00d7 scFv) bispecific antibodies exploits differential chain expression and affinity capture Sci Rep 10 7557","journal-title":"Sci Rep"},{"key":"374_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13024-020-00399-z","volume":"15","author":"L Serneels","year":"2020","unstructured":"L Serneels 2020 Modeling the \u03b2-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study alzheimer\u2019s disease Mol Neurodegener 15 60","journal-title":"Mol Neurodegener"},{"key":"374_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jnc.12937","volume":"132","author":"B Georgievska","year":"2015","unstructured":"B Georgievska 2015 Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter \u03b2-amyloid levels in the CNS J Neurochem 132 477 486","journal-title":"J Neurochem"},{"issue":"261","key":"374_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/scitranslmed.3009835","volume":"6","author":"YJ Yu","year":"2014","unstructured":"YJ Yu 2014 Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates Sci Transl Med 6 261 154","journal-title":"Sci Transl Med"},{"key":"374_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"WM Pardridge","year":"2020","unstructured":"WM Pardridge 2020 Blood-brain barrier and delivery of protein and gene therapeutics to brain Front Aging Neurosci 11 373","journal-title":"Front Aging Neurosci"},{"key":"374_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1357-2725(99)00070-9","volume":"31","author":"P Ponka","year":"1999","unstructured":"P Ponka CN Lok 1999 The transferrin receptor: role in health and disease Int J Biochem Cell Biol 31 1111 1137","journal-title":"Int J Biochem Cell Biol"},{"key":"374_CR38","first-page":"1452","volume":"14","author":"A Yogi","year":"2022","unstructured":"A Yogi 2022 Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor Pharm 14 1452","journal-title":"Pharm"},{"key":"374_CR39","first-page":"229","volume":"31","author":"F St-Gelais","year":"2006","unstructured":"F St-Gelais C Jomphe L-E Trudeau 2006 The role of neurotensin in central nervous system pathophysiology: what is the evidence? J Psychiatry Neurosci 31 229 245","journal-title":"J Psychiatry Neurosci"},{"issue":"84","key":"374_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/scitranslmed.3002254","volume":"3","author":"JK Atwal","year":"2011","unstructured":"JK Atwal 2011 A therapeutic antibody targeting BACE1 inhibits amyloid-\u03b2 production in vivo Sci Transl Med. 3 84 43","journal-title":"Sci Transl Med."},{"key":"374_CR41","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/bit.22135","volume":"102","author":"RJ Boado","year":"2009","unstructured":"RJ Boado Y Zhang Y Wang WM Pardridge 2009 Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse Biotechnol Bioeng 102 1251 1258","journal-title":"Biotechnol Bioeng"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00374-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-022-00374-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00374-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T13:11:34Z","timestamp":1664802694000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-022-00374-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1186\/s12987-022-00374-4","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"4 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted according to protocols approved by the local Ethical Committee of Laboratory Animals of the KU Leuven (governmental license LA1210579, ECD project number 213\/2020) following governmental and EU guidelines. Consent to participate is not applicable.since no human subjects were involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}